When two executives in the pharmaceutical industry step forward to complain the drug test results being published are not accurate, they don’t expect to be fired; and they don’t expect anyone to be stalked, beaten, or killed. They have no idea what they will be up against for revealing a secret that will cost their employer billions of dollars.

Aligor Pharmaceuticals has a new drug that they say will revolutionize cancer treatment, with the possibility of rescuing many in the final stages of the disease. Delexane is only weeks from FDA approval as the phase three trials conclude. The product is already generating millions of dollars with news of its arrival causing the stock price to soar. In a couple of months, the product will be released, and millions battling cancer are expected to benefit.

The problem is, the 65 percent success rate that resulted in the first two phases of the drug test has fallen to only 12 percent in phase three, the biggest test group of the product trials, but Aligor continues to publicize a 65 percent success rate. Witnessing the failures of phase three, Aligor executives Martin Cardenas and Justin Palmer repeatedly approach Aligor’s top management about the discrepancy between the results the company continues to publish and the results actually documented. To the CEO, their continued silence becomes a question of loyalty. They are both abruptly terminated - and the fight begins.

This is a timely story of a drug that is desperately needed in society. But Delexane is about to be rushed to the market prematurely, with its true performance and side effects hidden. And when a drug company doesn’t disclose the real data about a potential new drug to regulators or the public, there are millions of potential victims. Attorney Scott Winslow accepts representation of fired executives Cardenas and Palmer and goes to war with the pharma giant. Investigator Lee Henry goes to great lengths to access critical evidence.